The DYNLT3 Knockout A2780 Polyclonal Cells product consists of a heterogeneous population of A2780 cells that have undergone CRISPR/Cas9-mediated disruption of the DYNLT3 gene. This polyclonal knockout pool enables functional loss-of-function studies without clonal selection, preserving population-level heterogeneity and minimizing clonal artifacts. The DYNLT3 gene encodes a dynein light chain subunit critical for the retrograde transport machinery along microtubules. Disruption of this gene is expected to compromise dynein-dependent intracellular trafficking, offering a physiologically relevant model to investigate dynein function in cancer cell biology.
The A2780 host cell line is an established epithelial ovarian carcinoma model derived from an untreated patient. These cells exhibit an epithelial morphology and retain wild-type p53 status, making them particularly valuable for apoptosis and drug resistance studies. A2780 cells are extensively used in cisplatin resistance research, as they provide a reproducible platform for investigating chemosensitivity and the molecular mechanisms underlying ovarian cancer progression. The integration of the DYNLT3 knockout within this well-characterized cell background allows direct interrogation of dynein-mediated processes in a disease-relevant context.
DYNLT3 functions as an integral component of the cytoplasmic dynein complex, interacting with DYNC1H1, DYNC1I2, DYNLT1, and the dynactin complex to facilitate cargo binding and motor regulation. It mediates retrograde transport of signaling molecules, notably ??-catenin. In the Wnt/??-catenin pathway, WNT3A binding to Frizzled activates Dishevelled, inhibiting the Axin/APC destruction complex and stabilizing ??-catenin. DYNLT3?dynein transports ??-catenin along microtubules for perinuclear proteasomal degradation. DYNLT3 knockout likely impairs ??-catenin degradation, promoting its nuclear accumulation and transcriptional activity. Additionally, DYNLT3 interacts with spindle assembly checkpoint proteins, contributing to mitotic spindle organization.
In the A2780 ovarian carcinoma background, DYNLT3 disruption provides a powerful tool to dissect the interplay between intracellular trafficking and oncogenic signaling. Aberrant Wnt/??-catenin signaling is frequently associated with ovarian cancer metastasis and chemoresistance; therefore, DYNLT3 loss?of?function may alter ??-catenin localization and activity, impacting cell proliferation, migration, and drug sensitivity. Moreover, compromised dynein?dependent spindle organization could affect mitotic fidelity, providing insights into mechanisms of aneuploidy in cancer. This model thus enables the study of how dynein dysfunction contributes to tumor progression and may identify vulnerabilities that can be therapeutically exploited.
Researchers can employ this knockout cell population in a wide array of functional assays. Western blotting confirms DYNLT3 depletion, while immunofluorescence monitors ??-catenin subcellular redistribution. Quantitative RT?PCR of Wnt target genes assesses pathway activation. Migration and invasion assays evaluate metastatic potential, and apoptosis assays probe chemosensitivity. Co?immunoprecipitation experiments can assess dynein complex integrity. Drug sensitivity testing with cisplatin explores the role of dynein?mediated transport in resistance mechanisms. For further experimental guidance and product details, please contact Ascent Research.
